International Niemann–Pick Disease Alliance
ALACHUA, FL — (Marketwired — May 16, 2017) — CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that it will host a webinar to provide details of the Company’s recently initiated Phase I clinical trial in the U.S. and Phase I/II clinical trial in the EU, both evaluating CTD’s proprietary formulation of hydroxypropyl beta cyclodextrin, Trappsol® Cyclo™, for the treatment of Niemann-Pick Disease Type C (NPC). NPC is a rare and fatal genetic disease that damages the brain, lung, liver, spleen, and other organs. Speakers will include two of the site leaders from the ongoing Trappsol® Cyclo™ clinical trials, Dr. Caroline Hastings, UCSF Benioff Children’s Hospital Oakland, and Principal Investigator for the U.S. trial, and Dr. Reena Sharma, Salford Royal NHS Foundation Trust, The Mark Holland Metabolic Unit, Salford, United Kingdom, and Coordinating Investigator for the EU trial. Professor Alan Boyd, a globally recognized pharmaceutical physician, will provide highlights of CTD’s global compassionate use programs, some of which have been in existence since 2009. CTD will be represented on the webinar by N. Scott Fine, Chairman and CEO, and Dr. Sharon Hrynkow, Senior Vice President for Medical Affairs. Participants will be able to submit questions to the presenters.
The webinar will be held:
May 24, 12:00 pm – Eastern Daylight Time – for 1 hour
To register please go to this site: https://goo.gl/ok8e42
For further information on the clinical trials, see ClinicalTrials.Gov (NCT 02939547 and NCT 02912793) as well as CTD’s website at www.ctd-holdings.com, including Frequently Asked Questions at http://www.ctd-holdings.com/cyclodextrins/faq
About CTD Holdings:
CTD Holdings, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C, a rare and fatal genetic disease. Additional indications for the active ingredient in Trappsol® Cyclo™, are in development. For additional information, visit the company’s website: www.ctd-holdings.com
Safe Harbor Statement:
This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
LifeSci Advisors, LLC
Mark Krueger & Associates